CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-17 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award | +100,000 | 185,000 | ||
| 2023-03-17 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award | +92,735 | 277,735 | ||
| 2023-03-17 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award | +175,000 | 452,735 | ||
| 2023-03-17 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2023-03-17 | Floroiu Cezar Andrei President, Chief Exec Officer | Grant or award · Stock Option (right to buy) | +750,000 | 750,000 | ||
| 2023-03-17 | Berg Edward B SVP, General Counsel | Grant or award | +45,000 | 45,000 | ||
| 2023-03-17 | Berg Edward B SVP, General Counsel | Grant or award | +52,606 | 97,606 | ||
| 2023-03-17 | Berg Edward B SVP, General Counsel | Grant or award | +90,000 | 187,606 | ||
| 2023-03-17 | Berg Edward B SVP, General Counsel | Grant or award · Stock Option (right to buy) | +205,000 | 205,000 | ||
| 2023-03-17 | Berg Edward B SVP, General Counsel | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award | +45,000 | 113,750 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award | +56,652 | 170,402 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award | +90,000 | 260,402 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (right to buy) | +205,000 | 205,000 | ||
| 2023-03-17 | Tucker Sean SVP, Chief Scientific Officer | Grant or award | +45,000 | 172,631 | ||
| 2023-03-17 | Tucker Sean SVP, Chief Scientific Officer | Grant or award | +54,157 | 226,788 | ||
| 2023-03-17 | Tucker Sean SVP, Chief Scientific Officer | Grant or award | +90,000 | 316,788 | ||
| 2023-03-17 | Tucker Sean SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +205,000 | 205,000 | ||
| 2023-03-17 | Tucker Sean SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2023-03-17 | Cummings James F. Chief Medical Officer | Grant or award | +45,000 | 88,750 |
Page 8 of 10 · 198 trades